Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICIs), used for the treatment of solid and hematologic malignancies, come with the risk of immune-related adverse events (irAEs). Opportunistic infections (e.g., cytomegalovirus [CMV]) mimic irAE symptoms and are understudied in this population. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Panneerselvam, Kavea, Szafron, David, Amin, Rajan N., Wei, Dongguang, Tan, Dongfeng, Altan, Mehmet, Okhuysen, Pablo C., Shatila, Malek, Raju, Gottumukkala Subba, Thomas, Anusha S., Wang, Yinghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399572/
https://www.ncbi.nlm.nih.gov/pubmed/36061160
http://dx.doi.org/10.20524/aog.2022.0735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399572/
https://www.ncbi.nlm.nih.gov/pubmed/36061160
http://dx.doi.org/10.20524/aog.2022.0735

Ejemplares similares